{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:19:52Z","timestamp":1774930792367,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017238","name":"Sir Run Run Shaw Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472064"],"award-info":[{"award-number":["81472064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772387"],"award-info":[{"award-number":["81772387"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jbo.2022.100439","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:47:48Z","timestamp":1654948068000},"page":"100439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pexmetinib suppresses osteoclast formation and breast cancer induced osteolysis via P38\/STAT3 signal pathway"],"prefix":"10.1016","volume":"35","author":[{"given":"Zhiwei","family":"Jie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangde","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hejun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2022.100439_b0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","article-title":"The bone microenvironment in metastasis; what is special about bone?","volume":"27","author":"Bussard","year":"2008","journal-title":"Cancer Metastasis Rev."},{"issue":"8","key":"10.1016\/j.jbo.2022.100439_b0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbo.2022.100439_b0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2018.01.003","article-title":"Breast cancer bone metastases: pathogenesis and therapeutic targets","volume":"96","author":"Brook","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"8","key":"10.1016\/j.jbo.2022.100439_b0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","article-title":"Tumor metastasis: mechanistic insights and clinical challenges","volume":"12","author":"Steeg","year":"2006","journal-title":"Nat. Med."},{"issue":"6937","key":"10.1016\/j.jbo.2022.100439_b0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jbo.2022.100439_b0030","first-page":"241","volume":"64","author":"Ishiyama","year":"2015","journal-title":"Involvement of PU.1 in NFATc1 promoter function in osteoclast development, Allergology international : official journal of the Japanese Society of Allergology"},{"issue":"2","key":"10.1016\/j.jbo.2022.100439_b0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","article-title":"Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy","volume":"10","author":"Kozlow","year":"2005","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"4","key":"10.1016\/j.jbo.2022.100439_b0040","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.clbc.2012.04.003","article-title":"Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature","volume":"12","author":"Liu","year":"2012","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2022.100439_b0045","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00198-014-2885-0","article-title":"Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports","volume":"26","author":"Tan","year":"2015","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.jbo.2022.100439_b0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"10","key":"10.1016\/j.jbo.2022.100439_b0055","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/jbmr.3469","article-title":"LRP1 Suppresses Bone Resorption in Mice by Inhibiting the RANKL-Stimulated NF-\u03baB and p38 Pathways During Osteoclastogenesis","volume":"33","author":"Lu","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.jbo.2022.100439_b0060","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/leu.2012.71","article-title":"Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma","volume":"26","author":"Yang","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jbo.2022.100439_b0065","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-14-1765","article-title":"A phase I study of oral ARRY-614, a p38 MAPK\/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes","volume":"21","author":"Garcia-Manero","year":"2015","journal-title":"Clin. Cancer. Res."},{"issue":"4","key":"10.1016\/j.jbo.2022.100439_b0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jbmr.3334","article-title":"A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and I\u03baB\u03b1-Mediated p65 Nuclear Translocation","volume":"33","author":"Xie","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.jbo.2022.100439_b0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cellsig.2012.01.018","article-title":"The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis","volume":"24","author":"Bode","year":"2012","journal-title":"Cell. Signal."},{"issue":"42","key":"10.1016\/j.jbo.2022.100439_b0080","doi-asserted-by":"crossref","first-page":"15395","DOI":"10.1074\/jbc.RA119.010139","article-title":"STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription","volume":"294","author":"Yang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbo.2022.100439_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bse0380021","article-title":"Matrix metalloproteinases in cancer","volume":"38","author":"Hooper","year":"2002","journal-title":"Essays Biochem."},{"issue":"1","key":"10.1016\/j.jbo.2022.100439_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and Benefits of Bisphosphonate Therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.jbo.2022.100439_b0095","article-title":"Tumor cell p38 MAPK: A trigger of cancer bone osteolysis","volume":"2","author":"Liu","year":"2015","journal-title":"Cancer cell & microenvironment"},{"issue":"10","key":"10.1016\/j.jbo.2022.100439_b0100","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3390\/ijms19103004","article-title":"Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology","volume":"19","author":"Lee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2022.100439_b0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.intimp.2018.03.021","article-title":"Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-\u03baB pathways","volume":"58","author":"Li","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.jbo.2022.100439_b0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.mce.2013.03.010","article-title":"Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer","volume":"382","author":"Walker","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"11","key":"10.1016\/j.jbo.2022.100439_b0115","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: A review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"13","key":"10.1016\/j.jbo.2022.100439_b0120","first-page":"5137","volume":"61","author":"Alas","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jbo.2022.100439_b0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"Gritsko","year":"2006","journal-title":"Clin. Cancer. Res."},{"issue":"10","key":"10.1016\/j.jbo.2022.100439_b0130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrc906","article-title":"Transcription factors as targets for cancer therapy","volume":"2","author":"Darnell","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.jbo.2022.100439_b0135","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jbo.2022.100439_b0140","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","article-title":"Activation of stat3 in human melanoma promotes brain metastasis","volume":"66","author":"Xie","year":"2006","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.jbo.2022.100439_b0145","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1073\/pnas.0404100101","article-title":"Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C","volume":"101","author":"Dechow","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.jbo.2022.100439_b0150","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1038\/sj.onc.1207383","article-title":"Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis","volume":"23","author":"Xie","year":"2004","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.jbo.2022.100439_b0155","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/0008-5472.CAN-15-3062","article-title":"Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia","volume":"76","author":"Bachegowda","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jbo.2022.100439_b0160","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/0008-5472.CAN-09-1915","article-title":"Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer","volume":"70","author":"Min","year":"2010","journal-title":"Cancer Res."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742200029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742200029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:35Z","timestamp":1761941975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213742200029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"alternative-id":["S221213742200029X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100439","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pexmetinib suppresses osteoclast formation and breast cancer induced osteolysis via P38\/STAT3 signal pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100439"}}